MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

CDK4 inhibitors (CDK4i) earned Breakthrough Therapy Designation from the FDA last year and are entering phase III clinical trials in several cancers. However, not all tumors respond favorably to these drugs. CDK4 activity is critical for progression through G1 phase and into the mitotic cell cycle....

Descripción completa

Detalles Bibliográficos
Autores principales: Kovatcheva, Marta, Liu, David D., Dickson, Mark A., Klein, Mary E., O'Connor, Rachael, Wilder, Fatima O., Socci, Nicholas D., Tap, William D., Schwartz, Gary K., Singer, Samuel, Crago, Aimee M., Koff, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480747/
https://www.ncbi.nlm.nih.gov/pubmed/25803170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480747/
https://www.ncbi.nlm.nih.gov/pubmed/25803170

Ejemplares similares